Electronic Study for Anastrozole Pharmacovigilance Evaluation
Completed
- Conditions
- Early Breast Cancer
- Registration Number
- NCT00558168
- Lead Sponsor
- AstraZeneca
- Brief Summary
Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1850
Inclusion Criteria
- Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.
Read More
Exclusion Criteria
- Metastatic breast cancer patients, previous hormonal therapy, other malignancies.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method